Publications Discovery of ZN-c5, an Orally Bioavailable Selective Estrogen 2 Receptor Degrader (SERD) with Improved Pharmacokinetics 06 August 2025 Link To Article Previous article: An Antibody-toxin Conjugate Targeting CD47 Linked to the Bacterial Toxin Listeriolysin O for Cancer Immunotherapy Prev Next article: Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor Next
